Company Encyclopedia
View More
name
Shattuck Labs
STTK.US
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company’s lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology.
1.945 T
STTK.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking251/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-57.84%E
    • Profit Margin-5489.50%E
    • Gross Margin-661.80%E
  • Growth ScoreE
    • Revenue YoY-84.46%E
    • Net Profit YoY26.23%B
    • Total Assets YoY-10.19%E
    • Net Assets YoY-3.46%D
  • Cash ScoreE
    • Cash Flow Margin-1.82%D
    • OCF YoY-84.46%E
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio7.07%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shattuck Labs shares are trading higher after HC Wainwright & Co upgraded the stock from Neutral to Buy and announced a $6 price target.

    benzinga_article·
    US
    STTK
    +3.03%
    benzinga_article·
    US
    STTK
    +3.03%

    Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts

    Shattuck Labs, Inc. (NASDAQ:STTK) has received a consensus "Moderate Buy" rating from six brokerages. Analysts have varied opinions, with ratings ranging from sell to strong buy. The average target price is $3.00. Recent insider purchases and hedge fund activities indicate interest in the stock. Shattuck Labs is a clinical-stage biotech company focused on cancer and autoimmune therapeutics, with its lead candidate in Phase 1 trials.

    Market Beat·
    US
    STTK
    +3.03%
    Market Beat·
    US
    STTK
    +3.03%

    Shattuck Labs Inc. to Present at Piper Sandler Healthcare Conference

    Shattuck Labs Inc. will present at the Piper Sandler Healthcare Conference on December 2, 2025, in New York, and participate in the Evercore ISI HealthCONx Conference on December 4, 2025, in Coral Gables, FL. CEO Taylor Schreiber will give a presentation and join a fireside chat. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    STTK
    +3.03%
    Reuters·
    US
    STTK
    +3.03%

    Shattuck Labs: Hold Rating Amidst Key Milestones and Strong Financial Position

    H.C. Wainwright analyst Joseph Pantginis has maintained a Hold rating on Shattuck Labs (STTK) stock, citing key milestones and a strong financial position. The upcoming Phase 1 readout for SL-325 in Q2 2026 is crucial for the company's future, potentially reducing risk. Shattuck Labs has sufficient cash to support operations through at least one Phase 2 study, minimizing dilution risk. The third quarter of 2025 financial results showed a narrower loss than expected, supporting the Hold rating as the company focuses on advancing SL-325 while exploring bispecific antibodies.

    Tip Ranks·
    US
    STTK
    +3.03%
    Tip Ranks·
    US
    STTK
    +3.03%

    Shattuck Labs Reports Improved Financial Performance

    Shattuck Labs, Inc. (STTK) reported improved financial performance in its Q3 earnings for the quarter ending September 30, 2025. The company experienced a reduced net loss of $10.1 million, down from $16.7 million the previous year, despite a decline in revenue from collaborations. Cash and cash equivalents were $42.5 million, with total assets increasing to $100.3 million. Shattuck Labs remains focused on advancing its product pipeline and is confident in sustaining operations for the next twelve months amid a challenging economic environment.

    Tip Ranks·
    US
    STTK
    +3.03%
    Tip Ranks·
    US
    STTK
    +3.03%
    © 2025 Longbridge｜Disclaimer